ARISTOCORT
LOE ApproachingNDAORALSYRUP
Approved
Sep 1959
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ARISTOCORT is an oral syrup formulation of a corticosteroid approved in 1959 for anti-inflammatory and immunosuppressive indications. The exact indications are not specified in available data, but oral corticosteroids are typically used for allergic reactions, autoimmune conditions, and inflammatory disorders. As a small-molecule corticosteroid, it works by suppressing immune and inflammatory responses.
LOE Approaching
This legacy product is approaching loss of exclusivity with moderate competitive pressure (30/100), suggesting a contracting commercial team focused on defending market share rather than growth.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on ARISTOCORT offers limited career upside given its LOE trajectory and zero linked job openings. Roles focus on managing decline, cost optimization, and compliance rather than growth initiatives or innovation.
Brand ManagerField Sales Representative
Worked on ARISTOCORT at Astellas? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.